Hualan Vaccine Secures Approval for Clinical Trial of Freeze-Dried Hib Conjugate Vaccine

2025-08-13 / Read about 0 minute

Author：小编

Hualan Vaccine has recently received the Approval Notice for Drug Clinical Trial from the National Medical Products Administration for its innovative freeze-dried Haemophilus Influenzae Type b (Hib) conjugate vaccine. This vaccine, crafted through the conjugation of Hib capsular polysaccharide with tetanus toxoid protein, leverages freeze-drying technology to elicit a robust immune response and offer comprehensive protection. Furthermore, the company is actively developing a combined diphtheria, tetanus, and pertussis vaccine, which incorporates the Hib vaccine as an integral component. The intricate and time-consuming process of vaccine development underscores Hualan's commitment to advancing healthcare solutions.

Previous page：Jianfeng Group Announces Marketing Approval for Vo...

Next page：Euro Options Surge as Primary Tool for Shorting th...

Return to List

Hot Reading

2 day ago

Elon Musk's Grok AI Spread Ludicrous Misinformation After Charlie Kirk's Shooting, Saying Kirk Survived and Video Was Fake

1 day ago

OpenAI and Microsoft sign preliminary deal to revise partnership terms

2 day ago

OpenAI Execs Are Extremely Upset

2 day ago

FTC launches inquiry into AI chatbot companions from Meta, OpenAI, and others